[18F]Fluciclovine (trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid; anti-[18F]FACBC), a positron emission tomography tracer used for the diagnosis of recurrent prostate cancer, is transported via amino acid transporters (AATs) with high affinity (Km: 97-230 μM). However, the mechanism underlying urinary excretion is unknown. In this study, we investigated the involvement of AATs and drug ...

18F-fluciclovine (trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid) is an amino acid positron emission tomography (PET) tracer used for cancer staging (e.g., prostate and breast). Patients scheduled to undergo amino acid-PET are usually required to fast before PET tracer administration. However, there have been no reports addressing whether fasting improves fluciclovine-PET imaging. In this...

18F-Fluciclovine (trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid; anti-18F-FACBC) is a positron emission tomography (PET) tracer for diagnosing cancers (e.g., prostate and breast cancer). The most frequent metastatic organ of these cancers is bone. Fluciclovine-PET can visualize bony lesions in clinical practice; however, such lesions have not been described histologically. Methods: We in...

Abstract Background Positron emission tomography (PET) using anti-1-amino-3-18fluorine-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) shows preferential glioma cell uptake with low activity in normal brain. Dynamic contrast-enhanced (DCE) MRI may also be used to investigate regions of that do not show gadolinium-enhancement on post-contrast T1-weighted MR sequences (Gd-T1) and reflect t...

Abstract Background Following treatment of brain metastases, which can affect up to 40% patients with cancer, will typically be closely monitored serial magnetic resonance imaging (MRI) owing the high likelihood recurrence. The recommended follow-up modalities (CE-T1-weighted and FLAIR/T2-weighted MRI) have poor specificity, meaning that differentiation true disease from treatment-related chang...

Abstract BACKGROUND After radiation therapy (RT) for brain metastases (BM), differentiating necrosis from tumor recurrence remains challenging. PURSUE (NCT04410367) evaluated various measures of lesion 18F-fluciclovine uptake to establish image interpretation criteria (IIC) 18F-fluciclovine-PET accurately diagnose recurrent BM. METHODS Patients with solid BM and a previously irradiated ‘referen...

objective(s): the study objective was to assess the diagnostic performance of positron emission tomography (pet) for gliomas using the novel tracer 18f-fluciclovine (anti-[18f]facbc) and to evaluate the safety of this tracer in patients with clinically suspected gliomas.methods: anti-[18f]facbc was administered to 40 patients with clinically suspected high- or low-grade gliomas, followed by pet...

T hrough its Priority Review mechanism, the U.S. Food and Drug Administration (FDA) recently approved 2 radiopharmaceutical products for use as diagnostic PET agents. The first, approved on May 27, was Axumin (18F-fluciclovine) injection, indicated for use in PET imaging to identify suspected sites of prostate cancer recurrence in men with elevated levels of prostate-specific antigen (PSA) foll...

Abstract Background Amino acid PET radiopharmaceutical, 18F-fluciclovine, shows increased uptake in brain tumors relative to normal tissue and may be a useful tool for detecting recurrent metastases. Here, we report results from prospective pilot study evaluating the use of 18F-fluciclovine PET/CT distinguish radiation necrosis tumour progression among patients with metastases treated stereotac...